Pre-Market: See Why (TNFA) is #1 On Our Early Morning Watchlist

*Sponsored Market Crux Announces TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) As Its Next Potential Breakout Idea! Here’s Why (TNFA) Is #1 On This Morning’s Watchlist… Limited Float: With fewer than 3M shares, (TNFA)’s low float could lead to significant swing potential and heightened volatility. Recent Market Recognition: (TNFA) has moved approximately 44% in the last five days, surpassing key moving averages. Promising Clinical Results: MYMD-1® Phase 2a trials showed significant biomarker reductions with no serious adverse events, setting the stage for Phase 2b in 2025. Strategic Market Positioning: (TNFA) is the first to develop an oral TNF-α inhibitor for sarcopenia, targeting a $47.3B market. Breakthrough Therapeutics: (TNFA)’s MYMD-1® and Supera-CBD platforms address chronic inflammation, sarcopenia, and other unmet medical needs. Cutting-Edge R&D: Based in Baltimore’s biotech hub, (TNFA) leverages a strong ecosystem of research and innovation. Consider Adding (TNFA) To Your Radar This Week… December 19, 2024 Dear Reader, If you were tuned in early yesterday, you saw our profile trend from $0.6327 in the pre-market to $0.8194, marking an approximate 29% move in just 45 minutes after the opening bell. Now, we’re shifting gears and diving into the Pharma sector, where innovation meets momentum, to highlight our next potential breakout idea. Keep reading to find out why TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) has claimed the #1 spot on this morning’s watchlist. With less than 3M shares in its float, (TNFA) has the potential to witness significant swings if demand begins to shift. In fact, (TNFA) just moved approximately 44% in the last five days, from $1.05 on 12/13 to reaching $1.52 earlier today. This move pushed (TNFA) above several key moving averages including:  5-Day: 1.208 20-Day: 1.2557 50-Day: 1.3955 With the 100-Day at $1.5286, the 200-Day at $1.923, and the year-to-date high at $2.4184, it’s clear why (TNFA) should be considered for a spot on your radar. Let’s dive deeper into why TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is topping our watchlist ahead of tomorrow’s session.  TNF Pharmaceuticals, Inc.: Pioneering Breakthroughs in Lifespan-Extending Therapeutics Nestled in the vibrant biotech hub of Baltimore, Maryland, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is redefining how diseases are treated.  This clinical-stage pharmaceutical company is committed to extending healthy lifespans by targeting the root causes of disease, rather than merely addressing symptoms.  With its two groundbreaking therapeutic platforms—MYMD-1® and Supera-C-B-D—TNF Pharmaceuticals is poised to disrupt major pharmaceutical markets and meet significant unmet medical needs. MYMD-1®: A Game-Changer in Chronic Inflammation and Sarcopenia At the forefront of TNF Pharmaceuticals, Inc. (Nasdaq: TNFA)’s innovations is MYMD-1®, a clinical-stage small molecule dr-ug designed to regulate the immune system by controlling tumor necrosis factor-alpha (TNF-α) and other pro-inflammatory cytokines.  Chronic inflammation, driven by these cytokines, is a hallmark of many age-related diseases, including sarcopenia and frailty. The recent Phase 2a clinical trial results for MYMD-1® showcased the dr-ug’s potential to revolutionize sarcopenia treatment.  Presented at the prestigious 17th International Conference of the Society on Sarcopenia, Cachexia, and Wasting Disorders, the data demonstrated statistically significant reductions in key inflammatory biomarkers like TNF-α (P=0.008) and Interleukin-6 (P=0.03).  Patients aged 65 and older experienced these benefits without any serious adverse events, paving the way for the upcoming Phase 2b trial in early 2025. If approved, MYMD-1® would be the first oral TNF-α inhibitor for sarcopenia, offering a novel solution for the more than 50M individuals globally affected by the disease.  With the sarcopenia treatment market projected to grow to $4.02B by 2029, the potential for MYMD-1® extends far beyond its therapeutic benefits—it’s a significant avenue to reduce healthcare costs associated with age-related muscle loss and frailty. Supera-C-B-D: Advancing the Market for Therapeutic Derivatives TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is also breaking new ground with Supera-C-B-D, a synthetic derivative of (C-B-D).  Unlike traditional C-B-D products, Supera-C-B-D is designed to address chronic pain, addiction, and epilepsy with improved efficacy and consistency.  As the C-B-D market continues to expand—with FDA-approved dr-ugs like Epidiolex setting the stage for innovation—Supera-C-B-D aims to deliver next-generation treatments that blend the benefits of cannabinoids with pharmaceutical-grade precision. Strategic Market Potential The broader TNF inhibitor market, valued at over $40B in 2024, represents a significant commercial prospect for TNF Pharmaceuticals, Inc. (Nasdaq: TNFA).  With its unique position as a developer of an oral TNF-α inhibitor, the company could disrupt this space and capture a meaningful share of the market, which is expected to grow at a CAGR of 3.6% to $47.3B by 2029. Additionally, sarcopenia—a condition with no FDA-approved treatments—represents a critical unmet medical need.  Beyond the economic burden of +$40B in related hospitalization costs annually, sarcopenia impacts quality of life for many elderly and even young adults globally.  TNF Pharmaceuticals, Inc. (Nasdaq: TNFA)’s focus on addressing the disease itself, rather than just its symptoms, positions it as a leader in this burgeoning field. Commitment to Scientific Excellence Led by a team of visionary scientists and executives, including President and Chief Medical Officer Dr. Mitchell Glass, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is dedicated to rigorous research and development.  Dr. Glass emphasizes the company’s mission to deliver consequential therapeutic solutions for patients underserved by existing treatments. The Road Ahead With the Phase 2b trial for MYMD-1® set to commence in early 2025 and the ongoing development of Supera-C-B-D, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is on a trajectory to revolutionize healthcare.  By leveraging Baltimore’s robust life sciences ecosystem and Maryland’s unmatched resources, the company is positioning itself to make a lasting impact on the pharmaceutical industry. As TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) continues to deliver on its vision of extending healthy lifespans, the company exemplifies the potential of science and innovation to transform lives. 7 Reasons Why TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) Is #1 On This Morning’s Watchlist… 1. Limited Float: With fewer than 3M shares in the float, (TNFA) could experience significant swings if demand begins to shift. This limited float could create situations for volatility.  2. Recent Market Recognition: Over the last week, (TNFA) has displayed signs of increased market recognition, moving approximately 44% in just five days, while surpassing several key moving averages.   3. Promising Clinical Results: The Phase 2a trial of MYMD-1® presented significant biomarker reductions without serious adverse events, paving the way for the upcoming Phase 2b study in early 2025. 4. Strategic Market Positioning: As a developer of the first oral TNF-α inhibitor for sarcopenia, (TNFA) is uniquely positioned to impact an expanding market projected to grow to $47.3B by 2029. 5. Breakthrough Therapeutics: (TNFA)’s innovative platforms, MYMD-1® and Supera-C-B-D, target the underlying causes of chronic inflammation, sarcopenia, and other conditions, addressing critical unmet medical needs. 6. Innovative Leadership: Guided by visionary scientists and executives, including Dr. Mitchell Glass, (TNFA) is driven by a mission to deliver life-changing therapies for underserved populations. 7. Cutting-Edge R&D: (TNFA) is headquartered in the heart of Baltimore’s biotech hub, leveraging a robust ecosystem of scientific excellence and strategic resources to fuel innovation. Consider Adding TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) To Your Radar This Week… TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is making its mark as a forward-thinking leader in the pharmaceutical sector. With fewer than 3M shares in its float, the potential for significant swings exists if demand begins to change simply because of the scarcity. Over the last week, (TNFA) has displayed signs of increased market recognition, with shares moving approximately 44% in just five days, while surpassing several key moving averages. Adding to this momentum, the Phase 2a trial of MYMD-1® delivered promising results, paving the way for the Phase 2b study set for early 2025. By targeting critical unmet medical needs with its groundbreaking platforms, MYMD-1® and Supera-C-B-D, (TNFA) is addressing the causes of chronic inflammation, sarcopenia, and other conditions. As the first developer of an oral TNF-α inhibitor for sarcopenia, the company is positioning itself in a potential $47.3B market. Headquartered in Baltimore’s biotech hub, (TNFA) is driven by visionary leadership and supported by a robust ecosystem of research and development. With its focus on innovative therapies and a strong market presence, (TNFA) is positioning itself for continued advancements in the pharmaceutical field. It’s important to say this again… (TNFA) has less than 3M shares available in its float and has recently trended about several key moving averages.  TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is #1 on our watchlist this morning and now could be a good time for you to consider it. We are up bright and early watching (TNFA) right now so keep a lookout for my next update. I’ll follow up with you shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 12/18/2024 and ending on 12/19/2024 to publicly disseminate information about (TNFA:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (TNFA:US) via digital communications. These Funds were part of the funds that TD Media LLC received from a third party who did receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC or their members own shares of (TNFA:US). Please see important disclosure information here: https://marketcrux.com/disclosure/tnfa/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice